Literature DB >> 32319693

Epidemiology of Hepatocellular Carcinoma.

Katherine A McGlynn1, Jessica L Petrick2, Hashem B El-Serag3.   

Abstract

Liver cancer is a major contributor to the worldwide cancer burden. Incidence rates of this disease have increased in many countries in recent decades. As the principal histologic type of liver cancer, hepatocellular carcinoma (HCC) accounts for the great majority of liver cancer diagnoses and deaths. Hepatitis B virus (HBV) and hepatitis C virus (HCV) remain, at present, the most important global risk factors for HCC, but their importance will likely decline in the coming years. The effect of HBV vaccination of newborns, already seen in young adults in some countries, will be more notable as vaccinated cohorts age. In addition, effective treatments for chronic infections with both HBV and HCV should contribute to declines in the rates of viral-associated HCC. Unfortunately, the prevalence of metabolic risk factors for HCC, including metabolic syndrome, obesity, type II diabetes and non-alcoholic fatty liver disease (NAFLD) are increasing and may jointly become the major cause of HCC globally. Excessive alcohol consumption also remains an intractable risk factor, as does aflatoxin contamination of food crops in some parts of the world. While significant efforts in early diagnosis and better treatment are certainly needed for HCC, primary prevention efforts aimed at decreasing the prevalence of obesity and diabetes and controlling mycotoxin growth, are just as urgently required.
© 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2020        PMID: 32319693      PMCID: PMC7577946          DOI: 10.1002/hep.31288

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.298


  84 in total

1.  Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma.

Authors:  Manal M Hassan; Reham Abdel-Wahab; Ahmed Kaseb; Ahmed Shalaby; Alexandria T Phan; Hashem B El-Serag; Ernest Hawk; Jeff Morris; Kanwal Pratap Singh Raghav; Ju-Seog Lee; Jean-Nicolas Vauthey; Gehan Bortus; Harrys A Torres; Christopher I Amos; Robert A Wolff; Donghui Li
Journal:  Gastroenterology       Date:  2015-03-30       Impact factor: 22.682

2.  Thirty-year outcomes of the national hepatitis B immunization program in Taiwan.

Authors:  Chun-Ju Chiang; Ya-Wen Yang; San-Lin You; Mei-Shu Lai; Chien-Jen Chen
Journal:  JAMA       Date:  2013-09-04       Impact factor: 56.272

3.  High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism.

Authors:  M Frezza; C di Padova; G Pozzato; M Terpin; E Baraona; C S Lieber
Journal:  N Engl J Med       Date:  1990-01-11       Impact factor: 91.245

4.  High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1.2 million men.

Authors:  Hannes Hagström; Per Tynelius; Finn Rasmussen
Journal:  Gut       Date:  2017-03-20       Impact factor: 23.059

5.  Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.

Authors:  Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn
Journal:  Ann Intern Med       Date:  2015-03-17       Impact factor: 25.391

6.  Projections of primary liver cancer to 2030 in 30 countries worldwide.

Authors:  Patricia C Valery; Mathieu Laversanne; Paul J Clark; Jessica L Petrick; Katherine A McGlynn; Freddie Bray
Journal:  Hepatology       Date:  2017-12-23       Impact factor: 17.425

7.  Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma.

Authors:  Hashem B El-Serag; Thomas Tran; James E Everhart
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

8.  Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population.

Authors:  Stuart C Gordon; Lois E Lamerato; Loralee B Rupp; Jia Li; Scott D Holmberg; Anne C Moorman; Philip R Spradling; Eyasu H Teshale; Vinutha Vijayadeva; Joseph A Boscarino; Emily M Henkle; Nancy Oja-Tebbe; Mei Lu
Journal:  Clin Gastroenterol Hepatol       Date:  2013-10-06       Impact factor: 11.382

9.  GWAS identifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular carcinoma in chronic hepatitis B virus carriers.

Authors:  Shengping Li; Ji Qian; Yuan Yang; Wanting Zhao; Juncheng Dai; Jin-Xin Bei; Jia Nee Foo; Paul J McLaren; Zhiqiang Li; Jingmin Yang; Feng Shen; Li Liu; Jiamei Yang; Shuhong Li; Shandong Pan; Yi Wang; Wenjin Li; Xiangjun Zhai; Boping Zhou; Lehua Shi; Xinchun Chen; Minjie Chu; Yiqun Yan; Jun Wang; Shuqun Cheng; Jiawei Shen; Weihua Jia; Jibin Liu; Jiahe Yang; Zujia Wen; Aijun Li; Ying Zhang; Guoliang Zhang; Xianrong Luo; Hongbo Qin; Minshan Chen; Hua Wang; Li Jin; Dongxin Lin; Hongbing Shen; Lin He; Paul I W de Bakker; Hongyang Wang; Yi-Xin Zeng; Mengchao Wu; Zhibin Hu; Yongyong Shi; Jianjun Liu; Weiping Zhou
Journal:  PLoS Genet       Date:  2012-07-12       Impact factor: 5.917

Review 10.  Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis.

Authors:  Oliver John Kennedy; Paul Roderick; Ryan Buchanan; Jonathan Andrew Fallowfield; Peter Clive Hayes; Julie Parkes
Journal:  BMJ Open       Date:  2017-05-09       Impact factor: 2.692

View more
  244 in total

Review 1.  Hepatocellular carcinoma: epidemiology, screening, and assessment of hepatic reserve.

Authors:  S Z Frager; J M Schwartz
Journal:  Curr Oncol       Date:  2020-11-01       Impact factor: 3.677

2.  Th22/IL-22 mediates the progression of HBV-related hepatocellular carcinoma via STAT3.

Authors:  Jia Zhang; Zhou Liu; Lingpeng Liu; Mingwen Huang; Yong Huang
Journal:  Cytotechnology       Date:  2022-02-22       Impact factor: 2.058

Review 3.  Aspirin in Hepatocellular Carcinoma.

Authors:  Emanuela Ricciotti; Kirk J Wangensteen; Garret A FitzGerald
Journal:  Cancer Res       Date:  2021-04-23       Impact factor: 12.701

4.  Prognostic significance of systemic immune-inflammation index-based nomogram for early stage hepatocellular carcinoma after radiofrequency ablation.

Authors:  Yujing Xin; Yi Yang; Ning Liu; Yi Chen; Yanan Wang; Xinyuan Zhang; Xiao Li; Xiang Zhou
Journal:  J Gastrointest Oncol       Date:  2021-04

5.  SEC62 and SEC63 Expression in Hepatocellular Carcinoma and Tumor-Surrounding Liver Tissue.

Authors:  Markus Casper; Maximilian Linxweiler; Johannes Linxweiler; Richard Zimmermann; Matthias Glanemann; Frank Lammert; Susanne N Weber
Journal:  Visc Med       Date:  2021-01-12

Review 6.  The cGAS-STING Pathway: Novel Perspectives in Liver Diseases.

Authors:  Dongwei Xu; Yizhu Tian; Qiang Xia; Bibo Ke
Journal:  Front Immunol       Date:  2021-04-29       Impact factor: 8.786

7.  Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations.

Authors:  Wei Li; Hong Wu; Xuewen Xu; Yange Zhang
Journal:  Aging (Albany NY)       Date:  2021-04-18       Impact factor: 5.682

Review 8.  Repurposing metformin for the treatment of gastrointestinal cancer.

Authors:  Ademar Dantas Cunha Júnior; Arinilda Campos Bragagnoli; Felipe Osório Costa; José Barreto Campello Carvalheira
Journal:  World J Gastroenterol       Date:  2021-05-07       Impact factor: 5.742

9.  The Orphan Nuclear Receptor Gene NR0B2 Is a Favorite Prognosis Factor Modulated by Multiple Cellular Signal Pathways in Human Liver Cancers.

Authors:  Runzhi Zhu; Yanjie Tu; Jingxia Chang; Haixia Xu; Jean C Li; Wang Liu; Ahn-Dao Do; Yuxia Zhang; Jinhu Wang; Benyi Li
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

Review 10.  Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia-Pacific Region: A Review and Multidisciplinary Expert Opinion.

Authors:  Sadahisa Ogasawara; Su-Pin Choo; Jiang-Tao Li; Changhoon Yoo; Bruce Wang; Dee Lee; Pierce K H Chow
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.